Celebrate Memorial Day with a special flash sale from Benzinga Pro, offering 50% off exclusive market moving news. Take advantage of this offer to secure the financial freedom you and your family deserve. Claim your 50% discount now and stay informed with the latest updates.
Sharps Technology Inc (NASDAQ: STSS) is experiencing significant growth after signing a 5-year $200 million syringe sales agreement with Nephron Pharmaceuticals. With this deal, Sharps Technology expands its capabilities through the acquisition of InjectEZ specialty syringe manufacturing assets in South Carolina. This plant will be the only dedicated COC prefillable syringe manufacturing facility in North America, providing advanced production capabilities. Product delivery is expected to begin in late second-quarter 2025, with projected revenue of about $37 million in the first year.
If you’re interested in investing in STSS stock, you can visit a brokerage platform, buy an ETF that holds the stock, or allocate to a strategy in your 401(k) focused on acquiring shares. Given Sharps Technology’s position in the Health Care sector, an ETF tracking that sector can offer exposure to various companies within it. Data from Benzinga Pro shows that STSS has a 52-week high of $1.05 and a low of $0.17.
Don’t miss out on the Memorial Day flash sale from Benzinga Pro, offering 50% off exclusive market moving news to help you make informed financial decisions. Enter your email for a chance to win $500 in stock or crypto and receive Benzinga’s ultimate morning update, along with a free $30 gift card and more. Celebrate the holiday with special offers from Benzinga.
